StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.0
  1. Startseite
  2. /Verbindung

Clavulaninsure

Clavulanic Acid

HCID 5280980
Neue NotizNeue ReaktionAnfrage stellen
Druckvorschau

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
58001-44-8
Standard-SMILES
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21
InChIKey
HZZVJAQRINQKSD-PBFISZAISA-N
Summenformel
C8H9NO5
Durchschnittliche Molmasse
199,16 g/mol
Monoisotopische Masse
199,04807239

Namen und Bezeichner

Bevorzugter Name
Clavulanic Acid
IUPAC
(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Lokaler Name
Clavulaninsure
Englischer Name
Clavulanic acid
Summenformel
C8H9NO5
Molmasse
199.16

Namen und Synonyme

CLAVULANIC ACID58001-44-8Acido clavulanicoAcide clavulaniqueAntibiotic MM 14151acidum clavulanicumClavulansaeure(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acidMM 14151BRL-14151SerdaxinBRL 14151
Weitere Namen anzeigen
Clavulanate acid3008-bC06662MM-14151antibioticmm14151Clavulanate MonomerClavulanic acid USP/EP/BP
rx-10100(Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acidCHEBI:4894723521W1S24DTXSID2022830BRL14151(2R,3Z,5R)-3-(2-HYDROXYETHYLIDENE)-7-OXO-4-OXA-1-AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACIDClavulanate, Sodium

Datenbank-Bezeichner

CAS
58001-44-8
PubChem CID
5280980
DTXSID
DTXSID2022830
ChEMBL
CHEMBL777
ChEBI
CHEBI:48947
UNII
23521W1S24
EC Number
261-069-2
Nikkaji
J14.640D

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
-1,2
Polarare Oberfläche (TPSA)
87,1 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
5
Frei drehbare Bindungen
2
Schwere Atome
14
Formalladung
0
Komplexität
324

Experimentelle und physikochemische Eigenschaften

LogP · 2 Einträge

-2.3

-1.5

LogS0.23
Solubility3.37e+02 g/L
Boiling Point545.8
Melting Point · 2 Einträge

117.5-118

117.5 - 118 °C

Physical DescriptionSolid
Dissociation Constants2.7

Physikochemische Eigenschaften

Siedepunkt
545.8 · 545.8±50.0 °C(Predicted)
Dichte
1.65 · 1.65±0.1 g/cm3(Predicted)
storage temp.
4 °C, · 4°C, protect from light, stored under nitrogen

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Gefahrenhinweise

Regulatory InformationClavulanic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Toxikologische Informationen

Adverse Effects · 1 Eintrag

Clavulanic acid, when administered with amoxicillin, can cause some mild gastrointestinal adverse effects. These include vomiting, nausea, loose stools, and discomfort. Antibiotic-associated diarrhea due to amoxicillin-clavulanic acid treatment is the most common adverse effect. There is a higher incidence of diarrhea when clavulanic acid is added to amoxicillin compared to amoxicillin alone. Diarrhea is more common in those taking a high dose of the extended-release form of clavulanic acid and amoxicillin. Drug-induced pancreatitis from clavulanic acid and amoxicillin has occurred in a few cases.;When used for the treatment of urinary tract infections, this drug combination can cause candida vaginitis. Amoxicillin, in conjunction with clavulanic acid, is the most common cause of idiosyncratic drug-induced injury, specifically cholestatic liver injury, and this can lead to an increase in alkaline phosphatase and bilirubin levels. Since clavulanic acid administration is always in conjunction with amoxicillin, it is important to consider the adverse effects of amoxicillin alone as well. Hypersensitivity reactions to this drug combination, usually due to amoxicillin, can occur and result in dermatological reactions. Still, none of these allergic reactions are known to be due to clavulanic acid alone.

Toxicity Summary · 1 Eintrag

The toxicity of clavulanic acid alone is unknown. However, the toxic effects of amoxicillin/clavulanate have been reported. The most common toxic effect is an idiosyncratic drug-induced hepatic injury which leads to a mixed hepatocellular-cholestatic injury, and it is more common in older men. Amoxicillin-clavulanic acid is the most common cause of idiosyncratic drug-induced hepatic injury. Risk factors for hepatic injury include sex, cytochrome P450, and genetic polymorphisms. These risk factors should be examined before administering amoxicillin/clavulanate to reduce the risk of toxic and adverse effects. In addition to early diagnosis and discontinuation of the drug, N-acetylcysteine can be administered to minimize damage. Additionally, steroids can be given to decrease the time it takes to return hepatic enzymes and bilirubin levels to normal. Liver failure is also a rare but possible toxic effect of amoxicillin-clavulanic acid.

Chemie und Industrie

Pharmakologische Informationen

Protein BindingThe plasma protein binding of amoxicillin is about 25%.
Pharmacodynamics · 1 Eintrag

Clavulanic acid inactivates some beta-lactamase enzymes that are produced by bacteria, therefore preventing enzymatic destruction of amoxicillin. This helps to treat a variety of bacterial infections which would otherwise be resistant to antibiotics without the addition of clavulanic acid.

Mechanism of Action · 1 Eintrag

Clavulanic acid contains a beta-lactam ring in its structure that binds in an irreversible fashion to beta-lactamases, preventing them from inactivating certain beta-lactam antibiotics, with efficacy in treating susceptible gram-positive and gram-negative infections.

Biological Half-LifeThe half-life of clavulanic acid is reported to be similar to amoxicillin, and last 45-90 minutes. A study of radiolabeled clavulanic acid administered to 4 healthy volunteers determined a half-life of 0.8 h.
Metabolism/Metabolites · 1 Eintrag

Clavulanic acid is heavily metabolized to form the metabolites 2,5-dihydro-4-(2- hydroxyethyl)-5-oxo-1H-pyrrole-3-carboxylic acid and 1-amino-4-hydroxy-butan-2-one. The first metabolite was found to account for 15.6% of the dose while the second metabolite was reported to account for 8.8% of the dose in one pharmacokinetic study.

FDA Pharmacological Classification · 5 Einträge

23521W1S24

CLAVULANIC ACID

Established Pharmacologic Class [EPC] - beta Lactamase Inhibitor

Mechanisms of Action [MoA] - beta Lactamase Inhibitors

Clavulanic acid is a beta Lactamase Inhibitor. The mechanism of action of clavulanic acid is as a beta Lactamase Inhibitor.

MeSH Pharmacological ClassificationEndogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES.

Zugehörige Reaktionen

68
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 3626
HRID 3626als Eduktuspto-grants-1998_03
Reaktionsgleichung von HRID 127153
HRID 127153als Eduktuspto-grants-1981_03
Reaktionsgleichung von HRID 324260
HRID 324260als Produktuspto-grants-2001_04
Reaktionsgleichung von HRID 324261
HRID 324261als Produktuspto-grants-2001_04
Reaktionsgleichung von HRID 324262
HRID 324262als Produktuspto-grants-2001_04
Reaktionsgleichung von HRID 342856
HRID 342856als Eduktuspto-grants-1999_01
Reaktionsgleichung von HRID 368551
HRID 368551als Eduktuspto-grants-2000_10
Reaktionsgleichung von HRID 370438
HRID 370438als Produktuspto-grants-1985_07
Seite 1 von 9

Notizen zur Verbindung

Wird geladen…

Auf dieser SeiteGrundinformationenNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Weitere Aktionen
Neue NotizNeue ReaktionAnfrage stellen
Löslichkeit
2 O · H2O : 50 mg/mL (251.05 mM; Need ultrasonic)
Aggregatzustand
Solid
pka
3.68 · 3.68±0.20(Predicted)
Farbe
Off-white to light yellow

Regulatorische Informationen

Regulatory InformationClavulanic acid: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Sicherheitsdaten

Alarmwort
Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302
Absorption, Distribution and Excretion · 4 Einträge

Clavulanic acid, when taken orally, is well absorbed in the gastrointestinal tract. After administration of radiolabeled clavulanic acid to four human subjects, a minimum of 73% absorption and the average absolute bioavailability was calculated at 64%. The mean Cmax in a group of 8 healthy research volunteers was 2.098 ± 0.441 micrograms/ml in a pharmacokinetic study. The same study reported a mean Tmax of 1.042 ± 0.80 hours. Tmax is reported to be 40-120 minutes according to another pharmacokinetic study.

About 40 to 65% of the clavulanic acid is excreted as unchanged drug in urine during the first 6 hours following ingestion. The metabolites of clavulanic acid are found to be excreted in the urine and feces and as carbon dioxide in expired air. Clavulanate is cleared by both renal and non-renal processes. About 17% of radiolabeled dose of clavulanic acid was found to be exhaled in expired air and 8% of a dose was found to be excreted in the feces.

A study in 4 healthy volunteers administered a radiolabeled dose of clavulanic acid determined a volume of distribution of 12L.Clavulanic acid is distributed to various tissues and interstitial fluid. Clinically significant concentrations have been measured in the gallbladder, abdomen, skin, fat, and muscle tissues. Bile, pus, synovial and peritoneal fluids are also found to have therapeutic concentrations of clavulanic acid. Studies of animals have demonstrated that clavulanic crosses the placenta.

The clearance of clavulanic acid in a pharmacokinetic study of 4 healthy volunteers administered a radiolabeled dose of clavulanic acid was 0.21 l/min. Another resource indicates the average clearance of clavulanic acid is 12.20 liters/h/70 kg. Dose adjustments may be required in patients with renal failure.

Verwendung und Herstellung

Uses · 1 Eintrag

Use (kg) in Switzerland (2009): >2500;Use (kg; approx.) in Germany (2009): >2500;Use (kg) in USA (2002): 102000;Use (kg) in France (2004): 22699;Consumption (g per capita) in Switzerland (2009): 0.32;Consumption (g per capita; approx.) in Germany (2009): 0.031;Consumption (g per capita) in the USA (2002): 0.36;Consumption (g per capita) in France (2004): 0.38;Excretion rate: 0.525;Calculated removal (%): 92.1

Use ClassificationPharmaceuticals
Anwendungen · 2 Einträge

BeschreibungClavulanic acid is a mold product with only weak intrinsic antibacterial activity, but it is an excellent irreversible inhibitor of most β-lactamases. It is believed to acylate the active site serine by mimicking the normal substrate. Hydrolysis occurs with some β-lactamases, but in many cases, subsequent reactions occur that inhibit the enzyme irreversibly. This leads to its classification as a mechanism-based inhibitor (or so-called suicide substrate). The precise chemistry is not well understood, but when clavulanic acid is added to ampicillin and amoxicillin preparations, the potency against β-lactamase–producing strains is markedly enhanced.

Verwendenbeta-lactamase inhibitor

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

GlucoseSojabohnenmehlDextrinSoybean Flour

Nachgelagerte Produkte

Clavulanic Acid 2-AMino-2,4,4-triMethylpentane Salt

Ergänzende Hinweise

DefinitionChEBI: Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.